Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry

References

• Janow G, Schanberg LE, Setoguchi S, et al. The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010–2013. J Rheumatol. 2016;43(9):1755–1762.
   PubMed Web of Science ®Google Scholar
• Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: A retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27:491–496.
   PubMed Web of Science ®Google Scholar
• Alonzi T, Moretta A, Lazzaro D, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99(4):643–650.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146(5):598–604.
   PubMed Web of Science ®Google Scholar
• Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology. 2002;41(12):1444–1449.
   PubMed Web of Science ®Google Scholar
• Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania systemic onset juvenile arthritis registry (PASOJAR). J Rheumatol. 2008 February;35(2):343–348.
   PubMed Web of Science ®Google Scholar
• David J. Amyloidosis in juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9(1):73–78.
   PubMed Web of Science ®Google Scholar
• Grateau G. Musculoskeletal disorders in secondary amyloidosis and hereditary fevers. Best Pract Res. 2003;17(6):929–944.
   Web of Science ®Google Scholar
• De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol. 1998;25(2):203–207.
   PubMed Web of Science ®Google Scholar
• Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 2004;145(6):856–857.
   PubMed Web of Science ®Google Scholar
• Wulffraat NM, van Rooijen EM, Tewarie. R, et al. Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Int J Inflam. 2009;2012:16.
   Google Scholar
• Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2:28–34.
   PubMedGoogle Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–3732.
   PubMed Web of Science ®Google Scholar
• Palomo J, Dietrich D, Martin P, et al. The interleukin (IL)-1 cytokine family – balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76. DOI:10.1016/j.cyto.2015.06.017.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Inoue N, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015 Oct;160(2):277–281. .
   PubMed Web of Science ®Google Scholar
• Xia Y, Cui P, Li Q, et al. Extremely elevated IL-18 levels may help distinguish systemic-onset juvenile idiopathic arthritis from other febrile diseases. Braz J Med Biol Res. 2017;50(2):e5958.
   PubMed Web of Science ®Google Scholar
• Kudela H, Drynda S, Lux A, et al. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol. 2019 Feb 28;3: 4. .
   PubMedGoogle Scholar
• Scott IC, Ibrahim F, Simpson G, et al. A randomized trial evaluating anakinra in early active rheumatoid arthritis. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):88–93.
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005 Mar;52(3):818–825.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–2406.
   PubMed Web of Science ®Google Scholar
• Lequerré T, Quartier P, Rosellini D, et al. Société Francophone pour la Rhumatologie et les Maladies InflammatoiresenPédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):302–308.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study. Ann Rheum Dis. 2009;68:1613–1617.
   PubMed Web of Science ®Google Scholar
• Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 2019 Jul;71(7):1163–1173.
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Jager W, Noordman BJ, et al. Effectiveness of first‐line treatment with recombinant Interleukin‐1 receptor antagonist in steroid‐naive patients with new‐onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66:1034–1043. .
   PubMed Web of Science ®Google Scholar
• Bettiol A, Lopalco G, Emmi G, et al. Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases. Int J Mol Sci. 2019 Apr 17;20(8):1898. PMID: 30999610; PMCID: PMC6514653. .
   Web of Science ®Google Scholar
• Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheumatic Dis. 2004 Dec;63(12):1638–1644.
   PubMed Web of Science ®Google Scholar
• Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761–1769.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheumatism. 1997;40:1202–1209.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Huang B, et al. Childhood arthritis rheumatology research alliance; pediatric rheumatology collaborative study group; paediatric rheumatology international trials organisation. American college of rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011 July;63(7):929–936.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Bracciolini G, Ruperto N, et al. For the paediatric rheumatology international trials organization. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheumatism. 2012;64:2366–2374.
   PubMed Web of Science ®Google Scholar
• International council for harmonization and good clinical practice, ICH-GCP: guideline for good clinical practice. 2016. E6(R2) 2016. EMA/CHMP/ICH/135/1955.
   Google Scholar
• Altman DG. Analysis of survival times in practical statistics for medical research. London: Chapman and Hall; 1992. p. 365–393.
   Google Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008 May;58(5):1505–1515. .
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011 Feb;63(2):545–555. .
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–754.
   PubMed Web of Science ®Google Scholar
• Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol. 1998 Nov;37(11):1240–1242. PMID: 9851278. .
   PubMedGoogle Scholar
• Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12):1638–1644.
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003 Apr;48(4):1093–1101. PMID: 12687553. .
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Long term safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. Rheumatology. 2014;41:759–767.
   Web of Science ®Google Scholar
• Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19:256.
   PubMed Web of Science ®Google Scholar
• Aygun D, Sahin S, Adrovic A, et al. The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study. Clin Rheumatol. 2019;38:1025.
   PubMed Web of Science ®Google Scholar
• Brunelli JB, Schmidt AR, Sallum AME, et al. High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting. ModRheumatol. 2018;28:264–270.
   Web of Science ®Google Scholar
• Davies R, Southwood TR, Kearsley-Fleet L, et al. Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British society for paediatric and adolescent rheumatology etanercept cohort study. Arthritis Rheumatol. 2015;67:2487–2494.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Baddley JW, et al. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016;18:210.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145–159.
   PubMed Web of Science ®Google Scholar
• Kineret (anakinra) 100 mg/0.67 ml solution for injection in preflled syringe. London: European Medicines Agency; 2018.
   Google Scholar
• Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018 Jul-Aug;36(4):668–675. Epub 2018 Mar 2. PMID: 29533755.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–1660.
   PubMed Web of Science ®Google Scholar